Overview of Immunomodulating Therapies: Practical Considerations for Treatment
A Continuing Medical Education
This program is supported by an educational grant from Teva Neuroscience.

This program provides a comparative overview of the immunomodulating therapies for MS, including a review of their mechanisms of action, a discussion of current MRI concepts of disease activity and destructive pathology as they relate to the effects of the immunomodulators, and a review of their long-term effects and safety.

The University of Cincinnati College of Medicine designates this educational monograph for a maximum of 1.0 hour of Category 1 credit toward the AMA Physician"s Recognition Award (PRA). Each physician should claim only those hours that he/she actually spent in the activity. This continuing educational monograph has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint sponsorship of the University of Cincinnati College of Medicine and BioScience Communications. The University of Cincinnati College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Omar A. Khan, MD, is an Associate Professor of Neurology and Director of the Multiple Sclerosis Clinic at Wayne State University School of Medicine in Detroit, Michigan. Dr. Khan received his medical degree from Allama Iqbal Medical College, University of the Panjab in Lahore, Pakistan. He completed his training in internal medicine at the Jewish Hospital of Cincinnati, and neurology residency training at the Medical College of Virginia at Richmond, Virginia. He received his postdoctoral fellowship training in neuroimmunology and clinical multiple sclerosis at the University of Maryland in Baltimore, Maryland.

Dr. Khan is a member of many professional societies, including the American Academy of Neurology, the Clinical Immunology Society and the American Academy of Immunotherapy. He currently serves as an ad hoc reviewer for Neurology, the Journal of Neurological Sciences, and Clinical and Diagnostic Laboratory Immunology.

Dr. Khan"s current principal research interests include the immunoregulation of disease activity in multiple sclerosis and other immune-mediated disorders of the central nervous system. Dr. Khan is currently and has served as principal investigator in several exploratory and phase III clinical trials in multiple sclerosis with cytokines and other immunoactive agents. Dr. Khan has published over 100 original research articles, review articles, and abstracts. He has also lectured extensively throughout the world.


Click the following link to view the CME http://www.expertsspeakout.uc.edu/